Nuvectis Pharma Inc
NASDAQ:NVCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sagax AB
STO:SAGA A
|
SE |
Nuvectis Pharma Inc
Short-Term Debt
Nuvectis Pharma Inc
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Short-Term Debt
$2.5B
|
CAGR 3-Years
1 257%
|
CAGR 5-Years
136%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Short-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nuvectis Pharma Inc
Glance View
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 8 full-time employees. The company went IPO on 2022-02-04. The firm focuses on the development of precision medicines for the treatment of unmet medical needs in oncology. The company uses target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Its product pipeline consists of NXP800 and NXP900. The firm's lead product candidate, NXP800 is a clinical-stage, oral small-molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The company targets ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancer. NXP800 uses a synthetic lethality strategy to reduce the protective factors in the cell that are modified by overactivation of HSP1, with ARID1a gene defective cells being vulnerable. NXP900 is an oral small molecule designed to inhibit the roto-oncogene tyrosine-protein kinase (SRC) and YES1 kinases. The company is used for the treatment of SRC-associated solid tumors.
See Also
What is Nuvectis Pharma Inc's Short-Term Debt?
Short-Term Debt
0
USD
Based on the financial report for Dec 31, 2025, Nuvectis Pharma Inc's Short-Term Debt amounts to 0 USD.
